Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients

Pfizer

Status: Terminated

Conditions: Metastatic Renal Cell Carcinoma

Treatments: Drug: Sunitinib malate

Study type: Observational

Funder types: Industry

Identifiers

NCT01073644

A6181118

Details and patient eligibility

About

The primary purpose is to monitor the safety and tolerability and effectiveness of sunitinib malate in the treatment of patients with metastatic renal cell carcinoma and gastrointestinal stromal tumor among filipino patients in usual clinical practice setting.

Full description

Open label

Enrollment: 3 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 18 years and above
• Diagnosed with metastatic renal cell carcinoma or gastrointestinal stromal tumor after imatinib treatment failure or intolerance

Exclusion criteria

• Subjects with conditions that are contraindicated with sunitinib malate

Trial design

3 participants in 1 patient group

Sunitinb malate

Treatment:

Drug: Sunitinib malate